We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Skinbiotherapeutics Plc | LSE:SBTX | London | Ordinary Share | GB00BF33H870 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 9.25 | 9.00 | 11.00 | - | 0.00 | 07:32:42 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 132k | -2.84M | -0.0163 | -5.67 | 16.1M |
Date | Subject | Author | Discuss |
---|---|---|---|
14/10/2020 19:16 | Bulls left holding, and buying, the cull - and announcement comes circa price of placing - so the retail bulls wouldnt dump it higher if knew sooner. Re stayed as buyers, for the sellers What a stink imo | spartan attack | |
14/10/2020 19:14 | "Fully Funded" It gets slapped circa 40% over the last few weeks, right to the time , and price of placing number A bit hooky if you ask me | spartan attack | |
14/10/2020 19:11 | Well, at least the sellers of circa -40% over the last few weeks , got lucky they didnt know this was coming, obviously lol | spartan attack | |
14/10/2020 19:08 | Id understand if it was to actually, with a contract, produce and launch But the RNS just rattles on about exploring stuff wow | spartan attack | |
14/10/2020 19:06 | recently too | spartan attack | |
14/10/2020 19:05 | I thought the CEO said this was fully funded? | spartan attack | |
14/10/2020 15:38 | Eczema no views then | best1467 | |
14/10/2020 15:33 | At least my concerns were answered in the interview this is not a standalone launch involving marketing of an own brand cosmetic so I am fine with the answer. He also said this was effectively 3rd in line of priority anyway | gary hindsight | |
14/10/2020 13:31 | Link was stripped out search for proactive investors and Skinbiotherapeutics | aquaesulis01 | |
14/10/2020 13:21 | Interview with Doug Quinn [...] | aquaesulis01 | |
14/10/2020 10:31 | Got to get its own lab first ffs. Just another start up? Smoke and mirrors | rayrac | |
14/10/2020 09:50 | Why not. SBTX has the option for the supply of as much lysate it wants at near cost. It could add another production distrution partner and be in control of its own brand with higher share of the margins. Its exactly the same model OPTI has. | slartybartfaster | |
14/10/2020 09:47 | Csre to comment on 4Ds history of confetti throwing?Placings of which dilute investors:£7.7m at 35p July 2020£22m at 50p (28% discount BTW - approximately 40.2% of the company's issued share capital) February 2020£30m at 790p December 2015£34.75m February 2015£21.5m at 150p June 2014£34.75 at 410p July 2014Grand total £167.2m | slartybartfaster | |
14/10/2020 09:43 | When he says own brand maybe it’s a white label with one of caths existing contacts? | shrewdmole | |
14/10/2020 09:36 | SP holding up well currently | judijudi | |
14/10/2020 09:36 | But to be clear, i will nevertheless be applying for a large number in the open offer..... | nobbygnome | |
14/10/2020 09:30 | shrewd, Agree SA is no mug It will be interesting to hear what he has to say now | judijudi | |
14/10/2020 09:18 | For me it appears the company is trying to run before it can walk. Talk of an own brand just doesn't make sense IMHO. They should be focussing on getting cashflow positive from the existing and upcoming deals and then look to expand. | nobbygnome | |
14/10/2020 09:18 | Jj Will take my open offer shares too! Plenty of cash now for obvious purposes and hopefully another global at the table. SA is no mug and one has to have some trust. Whenever sbtx is in demand you can’t buy for toffee so happy to have added at 17.5p broker said rsp was scarce on the offer side too he had to make calls to get me filled. | shrewdmole |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions